OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone610-882-1820
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$181.74 million
Profitability
Miscellaneous
Employees398
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions
What is OraSure Technologies' stock symbol?
OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."
How were OraSure Technologies' earnings last quarter?
OraSure Technologies, Inc. (NASDAQ:OSUR) announced its quarterly earnings results on Tuesday, August, 6th. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.04. The medical instruments supplier had revenue of $38.83 million for the quarter, compared to the consensus estimate of $41.48 million. OraSure Technologies had a net margin of 11.83% and a return on equity of 7.81%. OraSure Technologies's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.07 EPS. View OraSure Technologies' Earnings History.
When is OraSure Technologies' next earnings date?
What guidance has OraSure Technologies issued on next quarter's earnings?
OraSure Technologies updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of $0.24-0.26 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.25. The company issued revenue guidance of $165-170 million, compared to the consensus revenue estimate of $172.81 million.
What price target have analysts set for OSUR?
1 Wall Street analysts have issued twelve-month price objectives for OraSure Technologies' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate OraSure Technologies' share price to reach $7.00 in the next year. This suggests that the stock has a possible downside of 15.3%. View Analyst Price Targets for OraSure Technologies.
What is the consensus analysts' recommendation for OraSure Technologies?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for OraSure Technologies.
What are Wall Street analysts saying about OraSure Technologies stock?
Here are some recent quotes from research analysts about OraSure Technologies stock:
- 1. Canaccord Genuity analysts commented, "We stick with our HOLD rating and lower our PT from $9 to $7." (8/14/2019)
- 2. According to Zacks Investment Research, "OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. " (7/9/2019)
Has OraSure Technologies been receiving favorable news coverage?
News articles about OSUR stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. OraSure Technologies earned a news impact score of -1.2 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for OraSure Technologies.
Who are some of OraSure Technologies' key competitors?
Some companies that are related to OraSure Technologies include Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Inspire Medical Systems (INSP), Silk Road Medical (SILK), AtriCure (ATRC), Orthofix Medical (OFIX), Luminex (LMNX), Cryolife (CRY), Shockwave Medical (SWAV), Tactile Systems Technology (TCMD), Anika Therapeutics (ANIK), Cerus (CERS) and LeMaitre Vascular (LMAT).
What other stocks do shareholders of OraSure Technologies own?
Who are OraSure Technologies' key executives?
OraSure Technologies' management team includes the folowing people:
- Dr. Stephen S. Tang, Pres, CEO & Director (Age 58)
- Mr. Jack E. Jerrett, Sr. VP, Gen. Counsel & Sec. (Age 60)
- Mr. Anthony Zezzo II, Exec. VP & Bus. Unit Leader of Infectious Disease (Age 65)
- Mr. Brian L. Smith, Vice Chairman & EVP of Innovation - DNA Genotek, Inc. (Age 60)
- Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 51)
Who are OraSure Technologies' major shareholders?
OraSure Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Hawaiian Bank (0.14%) and State of Alaska Department of Revenue (0.08%). Company insiders that own OraSure Technologies stock include Brian Smith, Charles W Patrick, Jack E Jerrett, Mara G Aspinall, Roberto Cuca and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies.
Which institutional investors are buying OraSure Technologies stock?
OSUR stock was acquired by a variety of institutional investors in the last quarter, including First Hawaiian Bank and State of Alaska Department of Revenue. Company insiders that have bought OraSure Technologies stock in the last two years include Jack E Jerrett, Mara G Aspinall, Roberto Cuca and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.
How do I buy shares of OraSure Technologies?
Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OraSure Technologies' stock price today?
One share of OSUR stock can currently be purchased for approximately $8.26.
How big of a company is OraSure Technologies?
OraSure Technologies has a market capitalization of $509.85 million and generates $181.74 million in revenue each year. The medical instruments supplier earns $20.40 million in net income (profit) each year or $0.50 on an earnings per share basis. OraSure Technologies employs 398 workers across the globe.View Additional Information About OraSure Technologies.
What is OraSure Technologies' official website?
How can I contact OraSure Technologies?
OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]
MarketBeat Community Rating for OraSure Technologies (NASDAQ OSUR)
MarketBeat's community ratings are surveys of what our community members think about OraSure Technologies and other stocks. Vote "Outperform" if you believe OSUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
